DengiAll: India’s Homegrown Shield Against Dengue Nears Market Debut

India is on the brink of a groundbreaking medical achievement with the nearing completion of its first indigenous dengue vaccine, DengiAll. Developed collaboratively by the Indian Council of Medical Research (ICMR) and Panacea Biotec, this tetravalent vaccine is currently in the final phase of clinical trials and is expected to hit the market by mid-next year.  

 

The Phase 3 trials, involving over 10,000 healthy adult participants across 19 centers in 18 states and union territories, have shown promising results. The vaccine aims to provide comprehensive protection against all four strains of the dengue virus, a disease that claims thousands of lives annually during the monsoon season.  

 

DengiAll is poised to be a game-changer in India’s fight against dengue, offering a much-needed preventive solution to a disease that has long plagued the nation. Health experts believe that the vaccine’s introduction could significantly reduce the burden of dengue outbreaks, particularly in high-risk states like West Bengal, Uttar Pradesh, Rajasthan, and Kerala.  

 

This milestone underscores India’s growing capabilities in vaccine development and its commitment to addressing public health challenges through innovation and collaboration.  

 

Sources: Times Now, Times of India, News18.